Featured Research

from universities, journals, and other organizations

Revealing The Regulating Mechanism Behind Signal Transduction In The Brain

Date:
September 22, 2008
Source:
VIB (the Flanders Institute for Biotechnology)
Summary:
Our brain consists of billions of cells that continually transmit signals to each other. This dynamic process works only when the brain cells make contact correctly, or, in other words, when there is a good "synapse." An essential element in this process is a controlled protein production along with the synapse. VIB researchers are now discovering how the Fragile X protein (FMRP) ensures that protein production is controlled at synapse and regulated by brain activity.

Our brain consists of billions of cells that continually transmit signals to each other. This dynamic process − which enables us to learn, remember, and so much more − works only when the brain cells make contact correctly, or, in other words, when there is a good 'synapse'. An essential element in this process is a controlled protein production along with the synapse. VIB researchers connected to the Center for Human Genetics (K.U.Leuven) are now discovering how the Fragile X protein (FMRP) ensures that protein production is controlled at synapse and regulated by brain activity. Their findings are being published in the authoritative scientific journal Cell.

Fathoming the brain

Our 'gray matter' has yet to divulge all its secrets. For example, we do not yet fully understand how we are able to learn and remember things. We do know that dendrites and axons − the offshoots of brain cells − play a crucial role by making contact with each other in so-called synapses, through which signals are transmitted between different brain cells. Moreover, for properly functioning brain activity at a synapse, the right proteins must be present in the right concentrations. It has been known for some time that the brain's cells are able to produce proteins directly at the place where they are needed. But exactly how the subtle regulation of this process works is still to be discovered.

FMRP: controlling protein production

Claudia Bagni (VIB, K.U.Leuven, University of Rome Tor Vergata) has been studying the FMRP protein for years now. The absence of FMRP leads to the Fragile X syndrome, a mental handicap afflicting a thousand Belgians. In this particular syndrome, the synapses are not well-formed. So, it is no surprise that FMRP plays an important role in the development and functioning of the brain. The researchers have already shown that FMRP suppresses protein production, but how has remained a mystery.

A shared job with CYFIP1

Ilaria Napoli and her colleagues from Claudia Bagni's group are now discovering that FMRP cannot perform its job without another protein: CYFIP1. In a previous study, Claudia Bagni and her collaborators have shown that a reduced amount of FMRP in the brain increases the production of some neuronal proteins. The VIB researchers in Leuven have now elucidated the mechanism behind this. They have found that complexes of FMRP and CYFIP1 are located at the synapses and together suppress the local production of a number of proteins.

In the transduction of signals between brain cells, i.e. synaptic activation, CYFIP1 is released from the complex, whereby FMRP can no longer exercise its suppressing action. This is the impetus for the production of the proteins that are under the control of FMRP.

A change in the concentration of FMRP or CYFIP1 causes a disruption in this strict regulation of protein production. This, in its turn, causes diseases like Fragile X syndrome and Autism. Indeed, CYFIP1 has been recently found associated to Autism.

Importance of this research

With their research, Napoli and Bagni are shedding a bit more light on synapses in the brain − giving us more insight into learning and remembering, and also into a number of 'brain disorders'. We now understand that, through its absence, FMRP plays a role in diseases like Fragile X syndrome and Autism.


Story Source:

The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology). Note: Materials may be edited for content and length.


Cite This Page:

VIB (the Flanders Institute for Biotechnology). "Revealing The Regulating Mechanism Behind Signal Transduction In The Brain." ScienceDaily. ScienceDaily, 22 September 2008. <www.sciencedaily.com/releases/2008/09/080918170410.htm>.
VIB (the Flanders Institute for Biotechnology). (2008, September 22). Revealing The Regulating Mechanism Behind Signal Transduction In The Brain. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/09/080918170410.htm
VIB (the Flanders Institute for Biotechnology). "Revealing The Regulating Mechanism Behind Signal Transduction In The Brain." ScienceDaily. www.sciencedaily.com/releases/2008/09/080918170410.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins